Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 14/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17437873 | 0.87 | ROCK1 (0.54) | ROCK1ROCK2TSHRMAPTMEN1 | |
| SCHEMBL19902378 | 0.85 | TSHR (0.62) | ROCK1ROCK2TSHRMAPTKMT2A | |
| SCHEMBL19902337 | 0.82 | NPC1 (0.57) | ROCK1ROCK2TSHRMAPTLMNA | |
| SCHEMBL19902542 | 0.78 | LMNA (0.49) | ROCK1ROCK2KMT2ALMNA | |
| SCHEMBL17437844 | 0.76 | ROCK1 (0.49) | ROCK1ROCK2TSHRMAPTKMT2A | |
| SCHEMBL19902523 | 0.74 | ROCK1 (0.44) | ROCK1ROCK2KMT2ALMNARAB9A | |
| SCHEMBL17452599 | 0.74 | ROCK2 (0.54) | ROCK1ROCK2TSHRMAPTLMNA | |
| SCHEMBL1789261 | 0.73 | ATM (0.50) | ROCK1ROCK2MAPTLMNAALDH1A1 | |
| SCHEMBL17311750 | 0.72 | ROCK1 (1.00) | ROCK1ROCK2 | |
| SCHEMBL20229844 | 0.72 | ROCK1 (0.45) | ROCK1ROCK2TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | ROCK1 1/4885ROCK2 3/4885TSHR 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.